BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Brii Biosciences Secures Intellectual Property Rights for HBV Treatment from VBI Vaccines

Brii Biosciences Limited ("Brii Bio"), a leader in developing innovative treatments for diseases with significant unmet needs, has announced a strategic ac...

February 14, 2024 | News

Cathay Biotech and 3P.COM Forge Groundbreaking Joint Venture to Propel Sustainable Composite Innovations

In a strategic move towards sustainable innovation, Cathay Biotech Inc. of China and 3P.COM Co. Limited of South Korea have signed a landmark joint venture...

February 09, 2024 | News

Innovent Biologics Advances Novel Weight Management Drug Mazdutide with NDA Acceptance in China

This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...

February 08, 2024 | Regulatory

Nordic Bioscience Partners with Roche for PRO-C3 Biomarker in China

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH,...

February 06, 2024 | News

NouvNeu001 Marks Milestone in iRegene's c Trial with Successful First Patient Dosing

It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, an...

February 06, 2024 | News

Sirius Therapeutics Begins Phase 1 Trial for Long-Acting Factor XI siRNA Anticoagulant

"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events a...

February 04, 2024 | News

RemeGen Spotlights Three Major Advances in Global Cancer Battle, Closing Care Gap

Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and missi...

February 02, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

January 31, 2024 | News

Ractigen Therapeutics Partners with Utrecht Medical Center for saRNA Innovation in Neurodevelopmental Disorders

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...

January 30, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Merck and Mycenax Biotech Forge Partnership for Bioprocessing Innovation

Merck announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies Integrates company&rsq...

January 24, 2024 | News

WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...

January 24, 2024 | News

Sagimet Biosciences Reports Positive Results in Phase 2b Trial of Denifanstat for F2/F3 NASH

- Primary efficacy endpoints: NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in ...

January 24, 2024 | News

First Myeloma Patient Treated with CAR-T Successfully Released

The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target treatment,...

January 23, 2024 | News

Stay Connected